首页> 美国卫生研究院文献>Gut >Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis.
【2h】

Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis.

机译:肝硬化时内脏和肾脏的消除和儿茶酚胺的释放。代偿性肝硬化患者交感神经活动增强的证据。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Plasma noradrenaline (NA) and adrenaline (A) concentrations were determined in different vascular areas in 32 patients with cirrhosis and in nine controls during a right sided heart, liver, and renal vein catheterisation. The patients were divided into four groups: (I) Compensated (without ascites); (II) Recompensated on diuretic treatment because of former ascites; (III) Decompensated (with ascites) without treatment and (IV) Decompensated on diuretic treatment. Median arterial noradrenaline concentrations were 1.48, 1.07, 2.66, 4.14 and 2.50 nmol/l in controls, group I, II, III, and IV, respectively, the three last mentioned values being significantly raised (p less than 0.01). Median arterial adrenaline concentrations were not significantly increased. In patients arterial-hepatic venous extraction ratios of noradrenaline and adrenaline were on the average 25% (p less than 0.01) and 20% (p less than 0.02) less than those of the controls, indicating a slightly reduced splanchnic elimination of catecholamines in cirrhoses. In controls and group I significant renal venous-arterial noradrenaline differences were absent (0.00 and 0.03 nmol/l) while renal venous-arterial noradrenaline differences were significantly increased in groups II, III and IV (0.47, 0.53 and 0.68 nmol/l, p less than 0.01), indicating a significant net release of noradrenaline from the kidneys in recompensated and decompensated patients. Renal extraction of adrenaline was normal. In conclusion, increased arterial noradrenaline in decompensated and recompensated cirrhosis is only to a limited extent owing to reduced net splanchnic elimination. More likely the increase is caused by release of noradrenaline from the kidneys and possibly other organs indicating enhanced sympathetic nervous tone in these conditions.
机译:在32例肝硬化患者和9例正常心脏,肝脏和肾静脉导管中,在不同血管区域测定了血浆去甲肾上腺素(NA)和肾上腺素(A)的浓度。将患者分为四组:(I)补偿(无腹水); (二)由于前腹水,在利尿剂治疗中得到补偿; (III)未经治疗而代偿(腹水),以及(IV)在利尿剂治疗后代偿。在I,II,III和IV组的对照组中,动脉去甲肾上腺素的中位数浓度分别为1.48、1.07、2.66、4.14和2.50 nmol / l,后三个值显着升高(p小于0.01)。中动脉肾上腺素浓度没有明显增加。在患者中,去甲肾上腺素和肾上腺素的动脉-肝静脉提取率平均比对照组平均低25%(p小于0.01)和20%(p小于0.02),表明肝硬化中儿茶酚胺的内脏消除率略有降低。在对照组和I组中,没有明显的肾静脉-动脉去甲肾上腺素差异(0.00和0.03 nmol / l),而II,III和IV组的肾静脉-动脉去甲肾上腺素差异显着增加(0.47、0.53和0.68 nmol / l,p小于0.01),表明在补偿和失代偿患者中,去甲肾上腺素从肾脏中显着净释放。肾上腺素提取正常。总之,失代偿性和再代偿性肝硬化中动脉去甲肾上腺素的升高仅在一定程度上是由于减少了内脏净消除。增加的可能性更大可能是由于肾脏中去甲肾上腺素的释放以及其他器官的释放,表明在这些情况下交感神经张力增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号